Fondazione Telethon
Alessandro Betti has a diverse work experience spanning several industries and roles. Alessandro began their career as a Global Brand Manager at Barilla G&R F.lli SpA in 1997, where they worked until 2001. Alessandro then moved to Barilla France as a Marketing Manager for South/West Europe until 2003. Following this, Betti joined Philips as a Marketing & Sales Director, responsible for the SDA division's portfolio. Alessandro worked at Philips until 2007.
Afterwards, Betti joined Johnson & Johnson as a Marketing & CRM Director, and later transitioned to Ideal Standard International (Bain Capital) as a Marketing Director. In this role, they led the brand positioning and architecture for the entire brand and product portfolio in the consumer channel, particularly in Italy. Alessandro worked at Ideal Standard International until 2011 when they joined Indesit Company as a Marketing & Communication Director. Betti worked at Indesit Company until 2012.
In 2012, Betti became the Chief Fundraising Officer at Fondazione Telethon and held this position until 2019. Alessandro then became the Chief Executive Officer of Next Generation Diagnostics srl in 2019. Most recently, in 2022, Betti assumed the role of Chairman/President at InnovaVector, a company specializing in the production of viral vectors for gene therapy.
Throughout their career, Betti has demonstrated expertise in marketing, brand management, sales, and executive leadership.
Alessandro Betti completed a Master's degree in Marketing and Communication at Publitalia '80 in Milan from 1996 to 1997. Prior to that, they obtained a Bachelor's degree in Industrial Relations from Luiss Business School in Economics, attending from 1989 to 1994.
This person is not in any offices
Fondazione Telethon
Founded in 1990, Telethon Italy is one of the biggest biomedical charity in Italy, whose mission is to advance biomedical research towards the diagnosis, cure and prevention of muscular dystrophies and other human genetic diseases. Telethon Italy focuses on scientific research and does not offer healthcare, material assistance to patients and families or advocacy. Since 1991, Telethon Italy has invested 394 million Euros in research and funded 2,477 research projects on more than 445 human genetic diseases, which range from basic research to clinical trials.